+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Bronchiectasis Drugs Market by Drug Class, Route of Administration, End-Users - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011462
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Bronchiectasis Drugs Market grew from USD 1.39 billion in 2023 to USD 1.50 billion in 2024. It is expected to continue growing at a CAGR of 9.86%, reaching USD 2.70 billion by 2030.

The scope of research in the bronchiectasis drugs market involves understanding the landscape of medications used to manage chronic lung diseases characterized by abnormal dilation of bronchi, which leads to recurrent lung infections and airway damage. Bronchiectasis therapies broadly include antibiotics, expectorants, bronchodilators, and anti-inflammatory drugs to mitigate symptoms and improve quality of life. The necessity of this market arises from the increasing prevalence of chronic respiratory diseases, advancements in drug delivery systems, and an aging population more susceptible to such conditions. Key application areas involve hospital settings, clinic treatments, and home-care for patients requiring long-term management. End-users include healthcare providers, pharmacists, and patients themselves. Growth is influenced by investments in research and development (R&D) of novel therapeutics and the growing need for effective treatments due to enhanced disease awareness and diagnosis.

Market insights suggest expanding R&D into novel formulations and drug delivery technologies, including inhalable and biologic therapeutics, presents untapped potential opportunities. Furthermore, collaborations between biotech firms and research institutions can expedite the development of advanced therapies. Limitations affecting the market growth include high costs associated with developing new treatments, strict regulatory frameworks, and limited awareness in underdeveloped regions. These challenges can hinder market penetration and patient access to potentially life-saving medications. Innovations should focus on personalized medicine, genetic research to understand disease heritability, and the development of cost-effective, patient-friendly therapies. There is a clear opportunity to integrate artificial intelligence and machine learning to improve predictive diagnostics and treatment outcomes.

The bronchiectasis drugs market is dynamically evolving, with increasing patient awareness and technological advancements pushing its growth. It's essential for businesses to cultivate partnerships for diversified research and leverage digital tools to enhance therapeutic discovery and distribution. The nature of this market ensures that there is robust potential for those who navigate its complexities and focus on sustainable, patient-centered innovation.

Understanding Market Dynamics in the Bronchiectasis Drugs Market

The Bronchiectasis Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising number of respiratory tract infections and diseases
    • Government initiatives to raise awareness about respiratory health
    • Entry of short-acting and long-acting bronchiectasis drugs
  • Market Restraints
    • Resistance of pathogenic species to common bronchiectasis drugs
  • Market Opportunities
    • Innovations leading to the development of inhaled antibiotics and advanced bronchodilators
    • R&D activities and clinical trials to develop bronchiectasis drugs
  • Market Challenges
    • Regulatory concerns about the safety and efficacy of bronchiectasis drugs

Exploring Porter’s Five Forces for the Bronchiectasis Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Bronchiectasis Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Bronchiectasis Drugs Market

External macro-environmental factors deeply influence the performance of the Bronchiectasis Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Bronchiectasis Drugs Market

The Bronchiectasis Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Bronchiectasis Drugs Market

The Bronchiectasis Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Bronchiectasis Drugs Market

The Bronchiectasis Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchiectasis Drugs Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Lupin Limited, Mylan Inc. by Viatris Inc., Nephron Pharmaceuticals Corporation, Novartis AG, Perrigo Company PLC, Pfizer Inc., Prasco Laboratories, Ralington Pharma LLP, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Bronchiectasis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Drug Class
    • Anti-inflammatory Agents
    • Antibiotics
    • Bronchodilators
    • Mucolytics
  • Route of Administration
    • Inhalation
    • Intravenous
    • Oral
  • End-Users
    • Clinic
    • Hospital
    • Research Institute
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising number of respiratory tract infections and diseases
5.1.1.2. Government initiatives to raise awareness about respiratory health
5.1.1.3. Entry of short-acting and long-acting bronchiectasis drugs
5.1.2. Restraints
5.1.2.1. Resistance of pathogenic species to common bronchiectasis drugs
5.1.3. Opportunities
5.1.3.1. Innovations leading to the development of inhaled antibiotics and advanced bronchodilators
5.1.3.2. R&D activities and clinical trials to develop bronchiectasis drugs
5.1.4. Challenges
5.1.4.1. Regulatory concerns about the safety and efficacy of bronchiectasis drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Bronchiectasis Drugs Market, by Drug Class
6.1. Introduction
6.2. Anti-inflammatory Agents
6.3. Antibiotics
6.4. Bronchodilators
6.5. Mucolytics
7. Bronchiectasis Drugs Market, by Route of Administration
7.1. Introduction
7.2. Inhalation
7.3. Intravenous
7.4. Oral
8. Bronchiectasis Drugs Market, by End-Users
8.1. Introduction
8.2. Clinic
8.3. Hospital
8.4. Research Institute
9. Americas Bronchiectasis Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Bronchiectasis Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Bronchiectasis Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. BRONCHIECTASIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. BRONCHIECTASIS DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. BRONCHIECTASIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BRONCHIECTASIS DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 30. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. CANADA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 33. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. MEXICO BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 47. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 48. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 50. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 51. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. INDIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 56. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. JAPAN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 74. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. THAILAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. DENMARK BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 87. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. EGYPT BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 90. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. FINLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 93. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. FRANCE BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 96. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 97. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. GERMANY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 102. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. ITALY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 111. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. NORWAY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 114. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. POLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 117. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. QATAR BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 129. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. SPAIN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 138. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. TURKEY BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM BRONCHIECTASIS DRUGS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 147. BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 148. BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Bronchiectasis Drugs market, which are profiled in this report, include:
  • AdvaCare Pharma
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Lupin Limited
  • Mylan Inc. by Viatris Inc.
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Prasco Laboratories
  • Ralington Pharma LLP
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Group

Methodology

Loading
LOADING...

Table Information